Lisata Therapeutics, Inc.

Welcome to the LISADA Therapeutics 3rd Quarter 2025 Financial Results and Business Update Conference Call. Currently, all participants are in listen-only mode. Following management prepared remarks, we will hold a Q&A session. To ask a question at that time, please press star 1 on your telephone. You will then hear an automated message advising that your hand is raised. As a reminder, this call is being recorded today, Thursday, November 6th, 2025. I will now turn the call over to John Mendito, Vice President of Investor Relations and Corporate Communication at Lesata. Please go ahead, sir.

Thank you, operator, and good afternoon, everyone. Welcome to Lesata's third quarter 2025 conference call to discuss our financial results and to provide a business update. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer of Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer, and James Nisko, Senior Vice President of Finance and Treasury and Chief Accounting Officer. Shortly before this call, we issued a press release announcing our third quarter 2025 financial results, which is available under the Investors and News section of the company website, along with a webcast replay of this call. If you have not received the news release or if you'd like to be added to the company's email distribution list, please subscribe to the email alerts on the company website or email me at jmendito at lasada.com to be added. Before we begin, I remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Lasada. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, its forms 10Q, 8K, and 10K, which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Thursday, November 6, 2025. La Sada Therapeutics undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. With that, I will now turn the call over to Dr. David Mazzo. Dave?

Thank you, John, and good afternoon, everyone. It's my pleasure to provide the latest update of La Sada's recent business highlights, discuss our third quarter 2025 financial results, and give a report on the progress of our development programs. Building on the momentum from the first half of the year, LASADA achieved several development milestones involving Certepatide, including the announcement of encouraging preliminary results from multiple studies, including the ASCEND trial, the ILISTA trial, and the CENDIFOX trial, adding further corroboration to our expectations of the positive impact of Certepatide as part of various anti-cancer treatment regimens. On the business development front, we entered into a strategic alliance with GATC Health to use their Multinomics Advanced Technology Artificial Intelligence Drug Discovery Platform to identify product candidates for development. We also executed a non-exclusive global license agreement with Catalent in which Catalent gains access to Certepatide and its analogs for use as a payload for their SmartTag ADC technology platform. We continue to anticipate that the next several quarters will be a data and transaction-rich period for La Sada with several key milestones on the horizon. Following the review of our financial results, Dr. Kristen Buck, our Chief Medical Officer and Head of R&D, will provide an update on our ongoing and planned clinical studies, including timelines and key achievements. With that, I will now turn the call over to James Nisko, our Senior Vice President of Finance and Treasury and Chief Accounting Officer. James?